Tracking a targeted cancer therapy: can we predict who benefits most?
NCT ID NCT04090034
Summary
This study aims to better understand how patients with advanced neuroendocrine tumors (NETs) respond to a treatment called Peptide Receptor Radionuclide Therapy (PRRT). Researchers will collect detailed information from about 50 patients receiving this standard treatment to learn which patient characteristics are linked to better survival, treatment response, and side effects. The goal is to gather real-world data to help doctors make more informed decisions for future patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Clinical Research Institute at Methodist Health System
RECRUITINGDallas, Texas, 75203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Methodist Dallas Medical Center
ENROLLING_BY_INVITATIONDallas, Texas, 75203, United States
Conditions
Explore the condition pages connected to this study.